Corcept Therapeutics Inc (NASDAQ: CORT) stock suffered a major decline of -25.6% on 1/2/24. The shares closed at $24.16. Moreover, trading volume in this decline was exceptionally high at 843% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -23.7% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, CORT is expected to continue to be a Value Builder.
Corcept Therapeutics has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Corcept Therapeutics has a poor Appreciation Score of 18 but a very high Power Rating of 89, with the Neutral Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment